Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lymphoma, Follicular 2Urinary Bladder Neck Obstruction 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Primary Myelofibrosis 1Polycythemia Vera 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Obesity 1Neoplasms 1Myeloproliferative Disorders 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, B-Cell 1Lung Neoplasms 1Lower Urinary Tract Symptoms 1Erectile Dysfunction 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 4liposomal doxorubicin 3Carboplatin 3pembrolizumab 2Bevacizumab 21-dodecylpyridoxal 2poly(I).poly(c12,U) 1mirabegron 1disitamab vedotin 1apatinib 1anlotinib 1Tocotrienols 1Platinum Compounds 1Lenalidomide 1Interferon alpha-2 1Hyperthermic Intraperitoneal Chemotherapy 1Gemcitabine 1EP-100 membrane-disrupting peptide 1Cisplatin 1AC 7700 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Cancer Recurrent × mirabegron × Clear all
NCT06791460 2025-03-18

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

Obstetrics & Gynecology Hospital of Fudan University

Phase 2/3 Recruiting
296 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡